152 related articles for article (PubMed ID: 18072423)
1. [Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial].
Trnený M
Vnitr Lek; 2007 Oct; 53(10):1029-30. PubMed ID: 18072423
[No Abstract] [Full Text] [Related]
2. [Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma].
Belada D; Smolej L; Stepánková P; Beránek M; Dvoráková D; Bukac J; Malý J
Vnitr Lek; 2007 Oct; 53(10):1057-63. PubMed ID: 18072430
[TBL] [Abstract][Full Text] [Related]
3. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
[No Abstract] [Full Text] [Related]
5. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
Grillo-López AJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.
Buchegger F; Press OW; Delaloye AB; Ketterer N
Oncologist; 2008 Jun; 13(6):657-67. PubMed ID: 18586921
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis and treatment of follicular lymphoma].
Nishikori M
Nihon Rinsho; 2012 Apr; 70 Suppl 2():477-81. PubMed ID: 23134002
[No Abstract] [Full Text] [Related]
10. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.
Takao T; Kobayashi Y; Kuroda J; Omoto A; Nishimura T; Kamitsuji Y; Fukiya E; Nakamura C; Kimura S; Yoshikawa T
Am J Hematol; 2004 Dec; 77(4):419-20. PubMed ID: 15551361
[No Abstract] [Full Text] [Related]
11. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Colombat P; Salles G; Brousse N; Eftekhari P; Soubeyran P; Delwail V; Deconinck E; Haïoun C; Foussard C; Sebban C; Stamatoullas A; Milpied N; Boué F; Taillan B; Lederlin P; Najman A; Thièblemont C; Montestruc F; Mathieu-Boué A; Benzohra A; Solal-Céligny P
Blood; 2001 Jan; 97(1):101-6. PubMed ID: 11133748
[TBL] [Abstract][Full Text] [Related]
12. Follicular lymphoma, survival, and rituximab: is it time to declare victory?
Horning SJ
J Clin Oncol; 2008 Oct; 26(28):4537-8. PubMed ID: 18662966
[No Abstract] [Full Text] [Related]
13. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Landgren O; Dunleavy K; Wilson WH
J Natl Cancer Inst; 2009 Sep; 101(18):1287-8; author reply 1289-90. PubMed ID: 19687413
[No Abstract] [Full Text] [Related]
14. Remission of transient acantholytic dermatosis after the treatment with rituximab for follicular lymphoma.
Ishibashi M; Nagasaka T; Chen KR
Clin Exp Dermatol; 2008 Mar; 33(2):206-7. PubMed ID: 18076680
[No Abstract] [Full Text] [Related]
15. [New data prove therapeutic superiority. MabThera in follicular and mantle cell lymphoma].
Krankenpfl J; 2002; 40(5-6):161. PubMed ID: 12271501
[No Abstract] [Full Text] [Related]
16. Cryptic insertion of BCL2 gene into immunoglobulin heavy locus in follicular lymphoma with t(6;9)(p23;p13).
Yamamoto K; Okamura A; Inui Y; Yakushijin K; Murayama T; Matsuoka H; Minami H
Leuk Res; 2012 Sep; 36(9):e202-5. PubMed ID: 22658849
[No Abstract] [Full Text] [Related]
17. Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.
Hirata Y; Yokote T; Kobayashi K; Nakayama S; Miyoshi T; Akioka T; Hara S; Tsuji M; Takubo T; Hanafusa T
Leuk Res; 2009 Jun; 33(6):e13-6. PubMed ID: 18995899
[No Abstract] [Full Text] [Related]
18. [Update on lymphomas: 1997, a profitable year].
Coiffier B; Salles G
Bull Cancer; 1998 Jan; 85(1):45-7. PubMed ID: 9752346
[No Abstract] [Full Text] [Related]
19. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
Foran JM; Gupta RK; Cunningham D; Popescu RA; Goldstone AH; Sweetenham JW; Pettengell R; Johnson PW; Bessell E; Hancock B; Summers K; Hughes J; Rohatiner AZ; Lister TA
Br J Haematol; 2000 Apr; 109(1):81-8. PubMed ID: 10848785
[TBL] [Abstract][Full Text] [Related]
20. Factors predictive for response of follicular and mantle-cell lymphoma to rituximab.
Pfreundschuh M
Nat Clin Pract Oncol; 2006 Apr; 3(4):184-5. PubMed ID: 16596141
[No Abstract] [Full Text] [Related]
[Next] [New Search]